Axsome Therapeutics
Update in progressAXSM (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Axsome Therapeutics is a biopharmaceutical company focused on developing CNS therapies in the United States. Its commercial products include Auvelity for adults with major depressive disorder; Sunosi for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea; and AXS-07 (Symbravo), a rapid, multi‑mechanistic migraine treatment. It also develops AXS-05, AXS-12, AXS-14, and Solriamfetol, and collaborates with Duke University on AXS-05 smoking cessation. Founded 2012; New York.
Company score
- Sentiment
- 0.30
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.01
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.28
- Governance
- 0.03
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.20
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. Herriot Tabuteau M.D.
- Founded2012
- Employees1,346
- Websitewww.axsome.com
Identifiers
- ISINUS05464T1043
- FIGIBBG00B6G7GL7
- LEI549300EXGR0XLRJEIB95
- CUSIP05464T104
- CIK0001579428